share_log

United States Cellular Analyst Ratings

Benzinga ·  Aug 8, 2023 08:44
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/08/2023 JP Morgan Upgrades Neutral → Overweight
07/26/2023 -13.63% Morgan Stanley $26 → $27 Maintains Equal-Weight
07/25/2023 -13.63% Morgan Stanley $26 → $27 Maintains Equal-Weight
05/08/2023 -48.82% Wells Fargo $22 → $16 Maintains Underweight
02/07/2023 -23.22% Morgan Stanley $37 → $24 Maintains Equal-Weight
01/10/2023 -36.02% Wells Fargo $33 → $20 Downgrades Overweight → Underweight
11/08/2022 -23.22% JP Morgan $32 → $24 Upgrades Underweight → Neutral
11/07/2022 Raymond James Downgrades Strong Buy → Market Perform
08/08/2022 24.76% Raymond James $41 → $39 Maintains Strong Buy
05/09/2022 31.16% Raymond James $40 → $41 Maintains Strong Buy
04/19/2022 18.36% Morgan Stanley → $37 Downgrades Overweight → Equal-Weight
02/22/2022 5.57% Wells Fargo $36 → $33 Maintains Overweight
02/22/2022 27.96% Raymond James $43 → $40 Maintains Strong Buy
08/02/2021 15.16% JP Morgan $35 → $36 Downgrades Neutral → Underweight
07/22/2021 59.95% Morgan Stanley $50.5 → $50 Maintains Overweight
02/22/2021 11.96% JP Morgan $42 → $35 Downgrades Overweight → Neutral
01/14/2021 61.55% Morgan Stanley $57 → $50.5 Maintains Overweight
11/16/2020 15.16% Wells Fargo → $36 Reinstates → Overweight
08/31/2020 47.15% Citigroup $45 → $46 Maintains Buy
08/27/2020 82.34% Morgan Stanley $56 → $57 Maintains Overweight
08/10/2020 37.56% Raymond James $40 → $43 Maintains Strong Buy
07/08/2020 79.14% Morgan Stanley $57 → $56 Maintains Overweight
05/18/2020 27.96% Raymond James $39 → $40 Reiterates → Strong Buy
05/14/2020 8.77% B. Riley Securities $42 → $34 Maintains Neutral
04/22/2020 24.76% Raymond James $41 → $39 Maintains Strong Buy
04/09/2020 82.34% Morgan Stanley $63 → $57 Maintains Overweight
03/27/2020 34.36% JP Morgan $45 → $42 Maintains Overweight
03/02/2020 101.54% Citigroup $66 → $63 Maintains Buy
11/04/2019 56.75% Raymond James $53 → $49 Upgrades Outperform → Strong Buy
11/04/2019 43.95% JP Morgan → $45 Upgrades Neutral → Overweight
08/06/2019 27.96% Wells Fargo $50 → $40 Maintains Market Perform
08/06/2019 34.36% B. Riley Securities $50 → $42 Maintains Neutral
08/05/2019 47.15% JP Morgan → $46 Upgrades Underweight → Neutral
06/18/2019 106.33% Morgan Stanley $44 → $64.5 Upgrades Equal-Weight → Overweight
05/06/2019 69.55% Raymond James $56 → $53 Reiterates → Outperform
11/06/2018 79.14% Raymond James $43 → $56 Maintains Outperform
08/08/2018 63.15% Citigroup $49 → $51 Maintains Buy

What is the target price for United States Cellular (USM)?

The latest price target for United States Cellular (NYSE: USM) was reported by JP Morgan on August 8, 2023. The analyst firm set a price target for $0.00 expecting USM to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for United States Cellular (USM)?

The latest analyst rating for United States Cellular (NYSE: USM) was provided by JP Morgan, and United States Cellular upgraded their overweight rating.

When is the next analyst rating going to be posted or updated for United States Cellular (USM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United States Cellular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United States Cellular was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.

Is the Analyst Rating United States Cellular (USM) correct?

While ratings are subjective and will change, the latest United States Cellular (USM) rating was a upgraded with a price target of $0.00 to $0.00. The current price United States Cellular (USM) is trading at is $31.26, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment